BTIG has expanded its healthcare research coverage, adding Justin Zelin to its research and strategy division as a director. His biotech research coverage will include cell therapy, targeted oncology, immunology and auto-immune disease therapeutics.
Prior to BTIG, Mr. Zelin was a biotech equity research analyst at B. Riley Securities. He also had stints with Canaccord Genuity and SVB Leerink as a biotech equity research associate, and was a member of Harvard University’s teaching staff for more than five years.
In a statement, David Lenchus, director of research with BTIG, said Mr. Zelin’s formal training as a scientist, with direct experience working on immuno-oncology and infectious disease therapeutic development, will help uncover important analysis from the fundamentals of companies he covers.
“Justin’s expansive relationships and rich understanding of the industry offers our clients a unique perspective as they evaluate their investment opportunities,” Mr. Lenchus said, adding that biotechnology continues to be a core area of growth for the firm, which increasingly offers differentiated and actionable expertise for clients.
Mr. Zelin joins BTIG’s biotech team, which includes Bert Hazlett, Thomas Shrader, Ph.D., and Julian Harrison.
